Results 41 to 50 of about 52,643 (262)

ω3 Polyunsaturated Fatty Acids as Immunomodulators in Colorectal Cancer: New Potential Role in Adjuvant Therapies [PDF]

, 2016
Diet composition may affect the onset and progression of chronic degenerative diseases, including cancer, whose pathogenesis relies on inflammatory processes.
Anna Maria Mileo, Roberta Masella, Sandra Gessani, Stefania Miccadei   +3 more
core   +2 more sources

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Xeloda as first-line therapy of metastatic colorectal cancer-our experience [PDF]

Archive of Oncology, 2002
BACKGROUND: Results of phase III clinical studies comparing efficacy of Xeloda vs. standard 5-FU/FA protocols as first line therapy of metastatic colorectal carcinoma (MCRC), have shown better efficacy of Xeloda, with less toxic adverse effects, apart ...
Kovčin Vladimir, Ješić Rada, Krivokapić Zoran V., Andrić Zoran, Pavlović Aleksandra   +4 more
doaj   +1 more source

Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. [PDF]

, 2015
PURPOSE: To improve the outcomes of patients with castration-resistant prostate cancer (CRPC), there is an urgent need for more effective therapies and approaches that individualize specific treatments for patients with CRPC.
Berman-Booty, Lisa D., Ciment, Stephen J, de Leeuw, Renée, Den, Robert, Dicker, Adam P., Gomella, Leonard G., Kelly, William, Knudsen, Karen E., Lallas, Costas D., Schiewer, Matthew J., Trabulsi, Edouard J.   +10 more
core   +2 more sources

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Compliance with a protocol for acute lymphoblastic leukemia in childhood

Revista Brasileira de Hematologia e Hemoterapia, 2011
BACKGROUND: Remission rates achieved after the initial treatment of acute lymphoblastic leukemia may be similar in both developed and developing countries, but relapse rates are much higher in the latter.
Benigna Maria de Oliveira, Maria Thereza Macedo Valadares, Marcilene Rezende Silva, Marcos Borato Viana   +3 more
doaj   +1 more source

Relation between DNA damage measured by comet assay and OGG1 Ser326Cys polymorphism in antineoplastic drugs biomonitoring [PDF]

, 2015
Antineoplastic drugs are hazardous chemical agents used mostly in the treatment of patients with cancer, however health professionals that handle and administer these drugs can become exposed and develop DNA damage.
Brito, Miguel, Carolino, Elisabete, Gomes, Manuel C., Ladeira, Carina, Pádua, Mário, Viegas, Susana   +5 more
core   +3 more sources

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Reproductive adverse events in patients with non‐Hodgkin lymphoma treated with chemotherapeutic regimens including cyclophosphamide, doxorubicin, vincristine, prednisone or CHOP with rituximab: A systematic review and meta‐analysis

Pediatric Discovery
The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R‐CHOP) is the first‐line treatment for non‐Hodgkin lymphoma (NHL).
Rong Han, Jie Zhao, Chengjun Yu, Ling Wang, Long Chen, Yang Hu, Shengde Wu   +6 more
doaj   +1 more source

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation

Hematology, Transfusion and Cell Therapy, 2020
Background: The treatment of multiple myeloma (MM) has evolved significantly in the past decade, and new drug combinations have improved the response rates and prolonged survival.
Edvan De Queiroz Crusoe, Fabiana Higashi, Gracia Martinez, Rosane Bittencourt, Jorge Vaz Pinto Neto, Lais Sousa, Rodrigo Santucci, Roberto José Pessoa Magalhães, Gilberto Colli, Renata Ferreira Marques Nunes, Glaciano Ribeiro, Jandir Nicacio, Karla Richter Zanella, Jose Mauro Kutner, Andre Magalhaes, Danielle Leao, Abrahão Elias Hallack Neto, Walter Braga, Emanuella G Souza, Antonio Julio A.M. Guimaraes, Giovanna Steffenello Durigon, Dani Laks, Angelo Maiolino, Vania Tietsche de Moraes Hungria   +23 more
doaj   +1 more source